Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
Merck and iPS Academia Japan, Inc. (Kyoto, Japan) today announced a global licensing agreement for AJ's induced pluripotent stem (iPS) cell patent portfolio.
Merck, announced publication of a study showing that its Strat-M® synthetic membrane predicts skin permeation of chemical compounds during in vitro transdermal diffusion studies as effectively as human or animal skin.
Accurately determine the level of airborne pollutants, such as asbestos, oil mist, gaseous fluorides, aerosolized solvents and radioactive particles, that may be released as a result of your processes.
Merck today announced that the Korean Intellectual Property Office and the Israel Patent Office have each issued notices granting Merck's patent applications for the company's CRISPR technology.
Merck today announced that the Chinese Patent Office has issued a notice granting Merck's patent application for the company's CRISPR technology used in a genomic-integration method for eukaryotic cells.
Required by all regulatory bodies worldwide, bacterial retention testing (BRT) is a critical step in filter validation. To ensure a "best case" outcome, we conduct BRT using each client's "worst case" processing conditions and drug product.
Merck today announced that the Canadian Patent Office has issued a "Notice of Allowance" for Merck's patent application covering the company's CRISPR technology.